-
1
-
-
84859861616
-
The ongoing evolution of endpoints in oncology
-
McCain Jr JA. The ongoing evolution of endpoints in oncology. Manag Care. 2010;19(5 Suppl 1):1-11.
-
(2010)
Manag Care
, vol.19
, Issue.5
, pp. 1-11
-
-
McCain, J.A.1
-
2
-
-
84899911233
-
American Society of Clinical Oncology perspective: raising the bar for clinical trials by defining clinically meaningful outcomes
-
Ellis LM, Bernstein DS, Voest EE, Berlin JD, Sargent D, Cortazar P, et al. American Society of Clinical Oncology perspective: raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol. 2014;32:1277-80.
-
(2014)
J Clin Oncol
, vol.32
, pp. 1277-1280
-
-
Ellis, L.M.1
Bernstein, D.S.2
Voest, E.E.3
Berlin, J.D.4
Sargent, D.5
Cortazar, P.6
-
3
-
-
42949145995
-
Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer
-
Burzykowski T, Buyse M, Piccart-Gebhart MJ, Sledge G, Carmichael J, Lück HJ, et al. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J Clin Oncol. 2008;26:1987-92.
-
(2008)
J Clin Oncol
, vol.26
, pp. 1987-1992
-
-
Burzykowski, T.1
Buyse, M.2
Piccart-Gebhart, M.J.3
Sledge, G.4
Carmichael, J.5
Lück, H.J.6
-
4
-
-
71549143528
-
Detecting an overall survival benefit that is derived from progression-free survival
-
Broglio KR, Berry DA. Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst. 2009;101:1642-9.
-
(2009)
J Natl Cancer Inst
, vol.101
, pp. 1642-1649
-
-
Broglio, K.R.1
Berry, D.A.2
-
5
-
-
84896923380
-
Which patients with metastatic breast cancer benefit from subsequent lines of treatment? An update for clinicians
-
Palumbo R, Sottotetti F, Riccardi A, Teragni C, Pozzi E, Quaquarini E, et al. Which patients with metastatic breast cancer benefit from subsequent lines of treatment? An update for clinicians. Ther Adv Med Oncol. 2013;5:334-50.
-
(2013)
Ther Adv Med Oncol
, vol.5
, pp. 334-350
-
-
Palumbo, R.1
Sottotetti, F.2
Riccardi, A.3
Teragni, C.4
Pozzi, E.5
Quaquarini, E.6
-
6
-
-
84864004759
-
Overall survival: patient outcome, therapeutic objective, clinical trial end point, or public health measure?
-
Saad ED, Buyse M. Overall survival: patient outcome, therapeutic objective, clinical trial end point, or public health measure? J Clin Oncol. 2012;30:1750-4.
-
(2012)
J Clin Oncol
, vol.30
, pp. 1750-1754
-
-
Saad, E.D.1
Buyse, M.2
-
7
-
-
79959280313
-
Overall survival as the outcome for randomized clinical trials with effective subsequent therapies
-
Korn EL, Freidlin B, Abrams JS. Overall survival as the outcome for randomized clinical trials with effective subsequent therapies. J Clin Oncol. 2011;29:2439-42.
-
(2011)
J Clin Oncol
, vol.29
, pp. 2439-2442
-
-
Korn, E.L.1
Freidlin, B.2
Abrams, J.S.3
-
8
-
-
84929091968
-
Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)
-
Gourgou-Bourgade S, Cameron D, Poortmans P, Asselain B, Azria D, Cardoso F, et al. Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials). Ann Oncol. 2015;26:873-9.
-
(2015)
Ann Oncol
, vol.26
, pp. 873-879
-
-
Gourgou-Bourgade, S.1
Cameron, D.2
Poortmans, P.3
Asselain, B.4
Azria, D.5
Cardoso, F.6
-
9
-
-
84857635931
-
Relationship between OS and PFS in metastatic breast cancer (MBC): review of FDA submission data
-
Cortazar P, Zhang JJ, Sridhara R, Justice RL, Pazdur R. Relationship between OS and PFS in metastatic breast cancer (MBC): review of FDA submission data. J Clin Oncol. 2011;29(15 Suppl):Abstract 1035.
-
(2011)
J Clin Oncol
, vol.29
, Issue.15
-
-
Cortazar, P.1
Zhang, J.J.2
Sridhara, R.3
Justice, R.L.4
Pazdur, R.5
-
10
-
-
79955445696
-
Accelerated approval of oncology products: the food and drug administration experience
-
Johnson JR, Ning YM, Farrell A, Justice R, Keegan P, Pazdur R. Accelerated approval of oncology products: the food and drug administration experience. J Natl Cancer Inst. 2011;103:636-44.
-
(2011)
J Natl Cancer Inst
, vol.103
, pp. 636-644
-
-
Johnson, J.R.1
Ning, Y.M.2
Farrell, A.3
Justice, R.4
Keegan, P.5
Pazdur, R.6
-
11
-
-
84860496547
-
Progression-free survival: meaningful or simply measurable?
-
Booth CM, Eisenhauer EA. Progression-free survival: meaningful or simply measurable? J Clin Oncol. 2012;30:1030-3.
-
(2012)
J Clin Oncol
, vol.30
, pp. 1030-1033
-
-
Booth, C.M.1
Eisenhauer, E.A.2
-
12
-
-
77955066199
-
Sipuleucel-T immunotherapy for castration-resistant prostate cancer
-
Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411-22.
-
(2010)
N Engl J Med
, vol.363
, pp. 411-422
-
-
Kantoff, P.W.1
Higano, C.S.2
Shore, N.D.3
Berger, E.R.4
Small, E.J.5
Penson, D.F.6
-
13
-
-
77949895922
-
Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer
-
Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol. 2010;28:1099-105.
-
(2010)
J Clin Oncol
, vol.28
, pp. 1099-1105
-
-
Kantoff, P.W.1
Schuetz, T.J.2
Blumenstein, B.A.3
Glode, L.M.4
Bilhartz, D.L.5
Wyand, M.6
-
14
-
-
62649134676
-
Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial
-
James ND, Caty A, Borre M, Zonnenberg BA, Beuzeboc P, Morris T, et al. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial. Eur Urol. 2009;55:1112-23.
-
(2009)
Eur Urol
, vol.55
, pp. 1112-1123
-
-
James, N.D.1
Caty, A.2
Borre, M.3
Zonnenberg, B.A.4
Beuzeboc, P.5
Morris, T.6
-
15
-
-
77956634017
-
Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized Phase II trial
-
James ND, Caty A, Payne H, Borre M, Zonnenberg BA, Beuzeboc P, et al. Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized Phase II trial. BJU Int. 2010;106:966-73.
-
(2010)
BJU Int
, vol.106
, pp. 966-973
-
-
James, N.D.1
Caty, A.2
Payne, H.3
Borre, M.4
Zonnenberg, B.A.5
Beuzeboc, P.6
-
16
-
-
84882937605
-
Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS wild-type metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3) [abstract]
-
Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran S, et al. Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS wild-type metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3) [abstract]. J Clin Oncol. 2013;31(Suppl):Abstr LBA3506.
-
(2013)
J Clin Oncol
, vol.31
-
-
Heinemann, V.1
Weikersthal, L.F.2
Decker, T.3
Kiani, A.4
Vehling-Kaiser, U.5
Al-Batran, S.6
-
17
-
-
77955497798
-
Words of wisdom. Re: Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. Kantoff PW, Schuetz TJ, Blumenstein BA, et al
-
Finley DS, Pouliot F, Pantuck A. Words of wisdom. Re: Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Eur Urol. 2010;58:466.
-
(2010)
Eur Urol
, vol.58
, pp. 466
-
-
Finley, D.S.1
Pouliot, F.2
Pantuck, A.3
-
18
-
-
0030000227
-
MR of recurrent high-grade astrocytomas after intralesional immunotherapy
-
Smith MM, Thompson JE, Castillo M, Cush S, Mukherji SK, Miller CH, et al. MR of recurrent high-grade astrocytomas after intralesional immunotherapy. AJNR Am J Neuroradiol. 1996;17:1065-71.
-
(1996)
AJNR Am J Neuroradiol
, vol.17
, pp. 1065-1071
-
-
Smith, M.M.1
Thompson, J.E.2
Castillo, M.3
Cush, S.4
Mukherji, S.K.5
Miller, C.H.6
-
19
-
-
73149092567
-
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria
-
Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbé C, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15:7412-20.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 7412-7420
-
-
Wolchok, J.D.1
Hoos, A.2
O'Day, S.3
Weber, J.S.4
Hamid, O.5
Lebbé, C.6
-
20
-
-
37549069291
-
Docetaxel versus docetaxel plus gemcitabine as front-line treatment of patients with advanced non-small cell lung cancer: a randomized, multicenter phase III trial
-
Georgoulias V, Androulakis N, Kotsakis A, Hatzidaki D, Syrigos K, Polyzos A, et al. Docetaxel versus docetaxel plus gemcitabine as front-line treatment of patients with advanced non-small cell lung cancer: a randomized, multicenter phase III trial. Lung Cancer. 2008;59:57-63.
-
(2008)
Lung Cancer
, vol.59
, pp. 57-63
-
-
Georgoulias, V.1
Androulakis, N.2
Kotsakis, A.3
Hatzidaki, D.4
Syrigos, K.5
Polyzos, A.6
-
21
-
-
77955972041
-
Comparison of two standard chemotherapy regimens for good-prognosis germ cell tumors: updated analysis of a randomized trial
-
Grimison PS, Stockler MR, Thomson DB, Olver IN, Harvey VJ, Gebski VJ, et al. Comparison of two standard chemotherapy regimens for good-prognosis germ cell tumors: updated analysis of a randomized trial. J Natl Cancer Inst. 2010;102:1253-62.
-
(2010)
J Natl Cancer Inst
, vol.102
, pp. 1253-1262
-
-
Grimison, P.S.1
Stockler, M.R.2
Thomson, D.B.3
Olver, I.N.4
Harvey, V.J.5
Gebski, V.J.6
-
22
-
-
1342311015
-
Phase III study of N, N-diethyl-2-[4-(phenylmethyl) phenoxy]ethanamine (BMS-217380-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19
-
Reyno L, Seymour L, Tu D, Dent S, Gelmon K, Walley B, et al. Phase III study of N, N-diethyl-2-[4-(phenylmethyl) phenoxy]ethanamine (BMS-217380-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19. J Clin Oncol. 2004;22:269-76.
-
(2004)
J Clin Oncol
, vol.22
, pp. 269-276
-
-
Reyno, L.1
Seymour, L.2
Tu, D.3
Dent, S.4
Gelmon, K.5
Walley, B.6
-
23
-
-
79952487463
-
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
-
Cortes J, O'Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011;377:914-23.
-
(2011)
Lancet
, vol.377
, pp. 914-923
-
-
Cortes, J.1
O'Shaughnessy, J.2
Loesch, D.3
Blum, J.L.4
Vahdat, L.T.5
Petrakova, K.6
-
24
-
-
84923205214
-
Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane
-
Kaufman PA, Awada A, Twelves C, Yelle L, Perez EA, Velikova G, et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2015;33:594-601.
-
(2015)
J Clin Oncol
, vol.33
, pp. 594-601
-
-
Kaufman, P.A.1
Awada, A.2
Twelves, C.3
Yelle, L.4
Perez, E.A.5
Velikova, G.6
-
25
-
-
84952870535
-
A phase III, open-label, randomized study of eribulin versus capecitabine in patients with metastatic breast cancer: effect of post-progression anti-cancer treatments (PPT) and metastatic progression events on overall survival
-
San Antonio, TX, USA: Poster presented at the 36th Annual CTRC-AACR San Antonio Breast Cancer Symposium
-
Awada A, Kaufman PA, Yelle L, Cortes J, Wanders J, O'Shaughnessy J, et al. A phase III, open-label, randomized study of eribulin versus capecitabine in patients with metastatic breast cancer: effect of post-progression anti-cancer treatments (PPT) and metastatic progression events on overall survival. San Antonio, TX, USA: Poster presented at the 36th Annual CTRC-AACR San Antonio Breast Cancer Symposium; 2013.
-
(2013)
-
-
Awada, A.1
Kaufman, P.A.2
Yelle, L.3
Cortes, J.4
Wanders, J.5
O'Shaughnessy, J.6
-
27
-
-
0034594628
-
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
-
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-16.
-
(2000)
J Natl Cancer Inst
, vol.92
, pp. 205-216
-
-
Therasse, P.1
Arbuck, S.G.2
Eisenhauer, E.A.3
Wanders, J.4
Kaplan, R.S.5
Rubinstein, L.6
-
29
-
-
0000120995
-
A class of K-sample tests for comparing the cumulative incidence of a competing risk
-
Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Statist. 1988;16:1141-54.
-
(1988)
Ann Statist
, vol.16
, pp. 1141-1154
-
-
Gray, R.J.1
-
30
-
-
84887401662
-
Survival prediction in everolimus-treated patients with metastatic renal cell carcinoma incorporating tumor burden response in the RECORD-1 trial
-
Stein A, Bellmunt J, Escudier B, Kim D, Stergiopoulos SG, Mietlowski W, et al. Survival prediction in everolimus-treated patients with metastatic renal cell carcinoma incorporating tumor burden response in the RECORD-1 trial. Eur Urol. 2013;64:994-1002.
-
(2013)
Eur Urol
, vol.64
, pp. 994-1002
-
-
Stein, A.1
Bellmunt, J.2
Escudier, B.3
Kim, D.4
Stergiopoulos, S.G.5
Mietlowski, W.6
-
31
-
-
84859480685
-
The initial change in tumor size predicts response and survival in patients with metastatic colorectal cancer treated with combination chemotherapy
-
Suzuki C, Blomqvist L, Sundin A, Jacobsson H, Byström P, Berglund A, et al. The initial change in tumor size predicts response and survival in patients with metastatic colorectal cancer treated with combination chemotherapy. Ann Oncol. 2012;23:948-54.
-
(2012)
Ann Oncol
, vol.23
, pp. 948-954
-
-
Suzuki, C.1
Blomqvist, L.2
Sundin, A.3
Jacobsson, H.4
Byström, P.5
Berglund, A.6
-
32
-
-
84901789986
-
The components of progression as explanatory variables for overall survival in the Response Evaluation Criteria in Solid Tumours 1.1 database
-
Litiere S, de Vries EG, Seymour L, Sargent D, Shankar L, Bogaerts J, et al. The components of progression as explanatory variables for overall survival in the Response Evaluation Criteria in Solid Tumours 1.1 database. Eur J Cancer. 2014;50:1847-53.
-
(2014)
Eur J Cancer
, vol.50
, pp. 1847-1853
-
-
Litiere, S.1
Vries, E.G.2
Seymour, L.3
Sargent, D.4
Shankar, L.5
Bogaerts, J.6
-
33
-
-
84952870690
-
New lesions versus growth of existing disease: does it impact prognosis?
-
Grothey A, Heun JM, Branda M, Goldberg RM, Sargent DJ. New lesions versus growth of existing disease: does it impact prognosis? J Clin Oncol. 2011;29(Suppl):Abstr 2579.
-
(2011)
J Clin Oncol
, vol.29
-
-
Grothey, A.1
Heun, J.M.2
Branda, M.3
Goldberg, R.M.4
Sargent, D.J.5
-
34
-
-
84911164671
-
Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models
-
Funahashi Y, Okamoto K, Adachi Y, Semba T, Uesugi M, Ozawa Y, et al. Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models. Cancer Sci. 2014;105:1334-42.
-
(2014)
Cancer Sci
, vol.105
, pp. 1334-1342
-
-
Funahashi, Y.1
Okamoto, K.2
Adachi, Y.3
Semba, T.4
Uesugi, M.5
Ozawa, Y.6
|